2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
9
Plasma cell
2
Gastrointestinal
2
Genitourinary
1
Breast
1
Conditions
Rectal Neoplasms
2
Neoplasms by Site
1
Neoplasms
1
Colonic Neoplasms
1
Carcinoma
1
Interventions
Oxaliplatin
1439
Fluorouracil
1319
Capecitabine
1114
Gemcitabine
1057
Leucovorin
939
Bevacizumab
847
Irinotecan
830
Cisplatin
676
Radiotherapy
560
Cetuximab
482
pembrolizumab
435
Paclitaxel
401
Drug Therapy
358
Nivolumab
350
130-nm albumin-bound paclitaxel
329
Docetaxel
290
Sorafenib
288
S 1 (combination)
279
Folfox protocol
266
Albumin-Bound Paclitaxel
263
Surgical Procedures, Operative
258
lenvatinib
222
sintilimab
218
tislelizumab
214
durvalumab
212
regorafenib
209
Magnetic Resonance Spectroscopy
205
apatinib
204
Radiosurgery
204
Neoadjuvant Therapy
190
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
L-BLP25
×
Gastrointestinal
×
Clear all
NCT01462513
2018-02-13
LICC
Johannes Gutenberg University Mainz
Phase 2
Completed
122 enrolled
NCT01507103
2017-01-13
SPRINT
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
124 enrolled
9 charts